PSM submits comment opposing HHS’s proposed peptide enforcement discretion policy

November 16, 2026

The policy would expose patients to unproven substances that FDA’s career staff recommended not be used in compounding because of safety and other concerns.

She trusted her med spa with a “pharmacy grade” treatment. No one mentioned risks.

November 13, 2026

Paige Gordon asked her med spa about a peptide treatment. No one reviewed her health history or talked about potential risks. Months later, her cancer came back.

November 9, 2026: Woman’s cancer returns after taking med spa peptides

November 12, 2026

Paige Gordon bought a peptide promising glowing skin on the recommendation of a licensed nurse she’d been a patient of for years at a med spa. Two months ago, she was told her cancer returned.

November 2, 2026: HHS tells compounders it will not enforce peptide regulations

November 3, 2026

The policy effectively allows compounders to produce these drugs, which are massively understudied, even though they don’t meet federal criteria for compounding.

Statement on the FDA and HHS enforcement discretion policy for 503a compounding with certain peptides

October 28, 2026

“Today’s decision leaves Americans in a grey area as to whether peptides are safe or not, even though the FDA’s own scientists recommended against voting in favor of these substances due to concerns with evidence.”

October 26, 2026: PSM files citizen petition asking FDA not to allow compounding of peptides

October 27, 2026

The peptides in question are untested and poorly defined, and making them easier to compound is a threat to public safety.

October 19, 2026: Two deaths linked to bootlegged retatrutide

October 21, 2026

Two deaths have been linked to black market versions of retatrutide, as a British woman warns followers that taking an early dose of the drug “nearly killed” her.

PSM files Citizen Petition with FDA to stop unsafe compounding of untested peptides

October 21, 2026

Partnership for Safe Medicines filed a citizen petition (CP) with the FDA asking them to refrain from taking action to allow for compounding of drug products using seven peptide bulk drug substances (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon). Learn why here.

October 13, 2026: Mounting evidence that popular unapproved peptide causes cancers

October 15, 2026

Doctors reported that a man who injected the unregulated peptide he purchased at a gym developed a melanoma lesion after only taking the drug for five weeks.

Remembering Alex Boutin: the hidden risks of performance enhancing drugs

October 14, 2026

Alex took the advice of older gym veterans about how he could bulk up fast, setting off more than a decade of steroid and, eventually, unregulated peptide use.